

PATIENT INFORMATION

LABEL TUBES USING STICKERS WITH AT LEAST 2 IDENTIFIERS

FULL NAME

DATE OF BIRTHPATIENT ID / NRIC / FIN

GENDERPHONE NO.

☐ Male☐ Female

ADDRESS

PAST HISTORY OF CANCER?☐ YES☐ NO

Type of cancer :

Year of diagnosis :

PAYMENT (please tick):

☐ INPATIENT (for Parkway Hospitals Only) Refer to CDM codes stated for billing

☐ BILL CLINIC (specify)☐ PATIENT TO PAY☐ OTHERS (specify)

PHYSICIAN INFORMATION

ORDERING PHYSICIAN NAME

CLINIC / HOSPITAL NAME, PHONE NO. AND ADDRESS

EMAIL (FOR PDF REPORT TO BE SENT TO)

TEST INFORMATION

(Refer to Annex A for gene list)

☐ LucenceINSIGHT™ 50

TAT: 12 Working Days

☐ LucenceINSIGHT™ 12

TAT: 18 Working Days

☐ LucenceINSIGHT™ Women’s 7

TAT: 18 Working Days

☐ LucenceINSIGHT™ 5

TAT: 18 Working Days

Report Preference

PRINTABLE PDF AND
HARDCOPY INCLUDED FOR
ONE LANGUAGE

ONLY PRINTABLE PDF FOR
ONE LANGUAGE INCLUDED

☐ TICK FOR HARDCOPY
(CHARGEABLE)

Report Language

(CHARGES FOR MULTIPLE SELECTIONS APPLY)

☐ ENGLISH

☐ SIMPLIFIED CHINESE

☐ TRADITIONAL CHINESE

Note: If unselected, English is the default report language.

SPECIMEN INFORMATION

Blood in 2 Streck Tubes (9mL each, 18mL in total)

COLLECTION DATE AND TIME:

BLOOD COLLECTED AT (please tick):

☐ IN-PATIENT HOSPITAL☐ OUT-PATIENT LABORATORY☐ CLINIC

☐ GEH☐ MEH☐ MNH☐ PEH

☐ WARD (please specify):

ORDERING PHYSICIAN’S SIGNATURE & DATE

I confirm that I have obtained the consent of the patient to: 1) perform the tests requested herein; 2) disclose his/her personal data stated herein to Parkway Laboratory Services Ltd (“PLS”) and its Affiliates for (i) the purposes of carrying out of the tests requested and all other related matters before and after and (ii) for purposes stated in the Parkway Data Privacy Policy (available at <https://www.parkwaypantai.com/privacy>). The patient understands that the use, collection and disclosure of his/her personal data by PLS and its Affiliates shall be in accordance with the Parkway Data Privacy Policy. I acknowledge and agree that PLS may at any time, whether upon request from the patient or otherwise, disclose and release to the patient the patient’s personal data, report and specimens. I indemnify PLS for any loss or damage which PLS and its Affiliates may suffer arising from or in connection with the release of the patient’s personal data, report and specimens to the patient.

FOR PARKWAY LABORATORY SERVICES USE

ADMIN CODE

Leave blank if not applicable

LUCENCE’S LABORATORY USE

Test details. Lucence cannot accept blood from patients with allogenic bone marrow transplants or blood transfusions less than 2 weeks prior to specimen collection. LucenceINSIGHT™ is for screening purposes and not for recurrence assessment. This test reports variants that are considered somatic and excludes from reporting variants that are considered germline by laboratory and reporting processes.

Turnaround time. Calculated upon sample acceptance in our Singapore laboratory. All turnaround times for tests administered by Lucence are provided as an indicative guide only and are based on Lucence’s experience of the time taken for the majority of such test results to be delivered. ‘Working day’ refers to Mondays-Fridays, 9am-6pm only, excluding Saturdays, Sundays, public holidays, and eves of public holidays. The cut-off time for sample receipt at Lucence laboratory is 5.00pm on working days. Samples that arrive in our laboratory after 5.00pm shall only be accepted the following working day.

Consent. By signing this form, the ordering physician acknowledges that the individual/family member authorised to make decisions for the individual (collectively, the “Patient”) has been supplied information regarding and consented to undergo genetic testing. The ordering physician undertakes that all necessary consents from the Patient to whom the Personal Data relates either have been obtained, or at the time of disclosure will have been obtained, for Lucence’s collection, use, disclosure, processing, and/or transfer of the Personal Data for the services specified in this form and that such consents are valid and have not been withdrawn. “Personal Data” means any data which can be used to identify an individual, either on its own or together with other data to which the ordering physician or Lucence have access. Please contact us at privacy@lucence.com or visit www.lucence.com/privacy for more details on Lucence’s privacy policy.

Order terms. The services provided by Lucence are subject to further terms and conditions found at www.lucence.com/order-terms, all of which are incorporated herein by this reference.

LOCATION OF PARKWAY OUTPATIENT LABORATORIES (FOR BLOOD DRAW)

GLENEAGLES HOSPITAL ANNEXE BLOCK, #03-33, 6A NAPIER ROAD, S(258500) FAX: 65 6471 3394

GLENEAGLES HOSPITAL MEDICAL CENTRE, #02-01, 6A NAPIER ROAD,S(258500) FAX: 65 6471 3394

MOUNT ELIZABETH HOSPITAL MEDICAL CENTRE, 3 MOUNT ELIZABETH, #01-03 S(228510) FAX: 65 6887 3938

MOUNT ELIZABETH NOVENA HOSPITAL, #01-01, 38 IRRAWADDY ROAD, S(329563) FAX: 65 6933 0538

PARKWAY EAST HOSPITAL, 321, JOO CHIAT PLACE, LEVEL 2, S(427990) FAX: 65 6345 5053

FOR LUCENCE LABORATORY USE ONLY

RECEIVED DATE AND TIME	
LUCENCE STAFF INITIALS AND DATE	
TYPE OF TUBES:	VOL. OF BLOOD:
VOLUME OF PLASMA:	ORDER ID:
LUCENCE ID:	SECONDARY ID:
<div><div><input type="checkbox"/> SAMPLE ACCEPTED</div><div><input type="checkbox"/> SAMPLE REJECTED</div></div> <div>REASON: </div>	

CHANGES TO ORDERED TEST, PLEASE ATTACH PROOF OF REQUEST

DETAILS:

DATE AND TIME:

CHECKED BY:

DATE AND TIME:

Form B - Informed Consent and Authorization Form for LucenceINSIGHT™ TestsInstructions:

1. This form must be fully completed and signed by the patient.
2. If the patient is below 21 years old, has never been married and has sufficient capability to understand this procedure, this form should be signed by both the patient and the patient's parent/guardian. If the patient is below 21 years old, has never been married and does not have sufficient capability to understand this procedure, this form should be signed by the patient's parent/guardian.
3. If the patient is unable to give consent due to a lack of mental capacity, consent is required from either the appointed guardian (donee) or deputy who is duly authorised to give such consent; or where there is no appointed guardian (donee) or deputy, and in order of preference: the patient's spouse; adult son or daughter; either parent or guardian; an adult brother or sister; or any other person named by the patient as someone to be consulted on the matter in question or on matters of that kind.

GENERAL INFORMATION ABOUT MULTI-CANCER EARLY DETECTION TESTSWhat is the purpose of the test?

Lucence Diagnostics Pte. Ltd.'s ("Lucence") multi-cancer early detection test (the "Test") analyzes the changes and alternations of your genes based on blood samples that you provide ("Sample Material"). This information may help guide the next steps of diagnosis. The Test will only assess the genetic profile of your Sample Material to determine the presence or absence of a cancer signal. The Test will not provide any general information relating to your overall health and it does not replace any cancer screening tests or diagnostic tests.

What does it involve?

A sample of your blood will be taken (as further set forth in this form) and sent to Lucence and/or Lucence's laboratory in the United States, where it will be examined for genomic alterations and other information. Utilizing data from the analysis, the Test reports a presence or absence of a cancer signal. A localization signal is also derived and used to predict up to 2 sites where the cancer signal might have originated from ("Predicted Signal Localization"). Lucence will then send your healthcare provider a detailed report. Your healthcare provider will work with you to evaluate the results alongside other information such as your medical history and results from other tests to determine what next steps are right for you.

What do the results mean?

- "Cancer Signal: Detected" is an indication that cancer-associated signals have been detected by the Test. The result will include up to 2 Predicted Signal Localization sites that highlight where the signal may have originated from. The sites covered in both LucenceINSIGHT™ and LucenceINSIGHT™ PLUS are Breast, Cervix, Colorectum, Gastrointestinal Tract, Liver, Lung, Nasopharynx, Pancreas and Prostate. The sites covered only in LucenceINSIGHT™ PLUS are Acute Myeloid Leukemia, Bladder, Endometrium, Eye, Head and Neck, Kidney, Lymphoplasmacytic Lymphoma, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Oropharynx, Skin and Stomach. This means that you may need to undergo additional confirmatory testing as recommended by your healthcare provider.
- "Cancer Signal: Not Detected" is an indication that no cancer signal has been detected by the Test at this time. This does not rule out the possibility of cancer, and you should continue to follow your healthcare provider's recommendations on routine cancer screening.

What are the potential risks and benefits of the screening?

- Risks: You may feel anxious and undergo more tests and procedures if you have a false-positive test result (one that suggests there is cancer when there is none). Such tests and procedures may be invasive and unnecessary. Conversely, with a false-negative result (one that suggests no cancer when there actually is), you may choose to ignore symptoms and delay treatment. Finding cancers early may also lead to overdiagnosis and overtreatment. You may possibly face genetic discrimination, which may have implications on employment and insurance.
- Benefits: Finding cancers early may increase the chances of recovery and survival, as early-stage cancers are easier to treat before they spread or before symptoms develop.

What are the risks and limitations of genetic analysis?

- Physical Risks: The Test can be administered via a blood sample (a "Blood Test"). When we run a Blood Test, a sample of your blood will be removed in a clinical setting by a trained healthcare professional, doctor, or nurse, using a needle. The risks associated with a Blood Test are minimal and include temporary discomfort, pain, bruising and, rarely, possible infection at the blood draw site.
- Additional Risks: The Test only studies the applicable Sample Material with respect to the specific cancers being screened for. The Test is not a diagnosis and does not screen for all genetic diseases or abnormalities. In addition, the accuracy of any genetic test, including the Test, is not guaranteed. All results of any Test and the implications of such results should be discussed with your healthcare provider.
- There are some possible causes of inaccurate or inconclusive results for the Test. These include: (1) Sampling problems, including freezing of Sample Material during shipping, or poor Sample Material quality. (2) Technical problems may include rare variation in the DNA of the individual. (3) Presence of mutations or genetic variations, which significance is not yet understood.

Withdrawal from testing

You may withdraw from the Test at any time, or choose not to learn of the results of your test. If the analysis is already underway, however, you will be charged a fee determined by Lucence, based on services provided and any amounts paid will not be refunded.

Management of results / Personal Data

1. Personal data means data, whether true or not, about an individual who can be identified from that data; or from that data and other information to which the organization has or is likely to have access ("Personal Data"). The Personal Data Lucence may, from time to time collect from you include your name, nationality, date of birth, sex, e-mail address, telephone number, mailing address, or passport number, your image (in the form of photographs), your medical history, patient history, allergy information, test results of genetic analysis, and any other medical and health records.
2. Lucence may collect, use, disclose, process, and transfer your Personal Data for the following purposes, but always in accordance with applicable laws and regulations:
 - a. providing you with healthcare, diagnostic and other services of Lucence, its affiliates, partners and related companies and for its company processes;
 - b. administrative purposes (e.g., processing orders; collecting payment; creation and maintenance of medical and business records; verifying identity and conducting screenings, due diligence and credit checks; responding to your queries; addressing claims or disputes; compliance with internal policies; and enforcing obligations to Lucence);
 - c. business operations (e.g., compliance with regulatory obligations, accounting, audit and record keeping, planning, product monitoring/assessment, quality control, training, product testing/development); and/or
 - d. research into new treatments and protocols (subject always to the applicable laws and codes of conduct).

3. The results of your Test, including your genetic data, will form part of your confidential medical records and Personal Data. These results will be accessible by your treating physician and his/her hospital or clinic, in addition to Lucence, and may be shared with other healthcare providers for medical treatment and healthcare purposes. Each of the foregoing parties has an obligation to keep your records confidential, in accordance with applicable laws and regulations.
4. Your Test results and clinical data may be added to and retained in databases for a reasonable period in accordance with Lucence's legal and business purposes, and subject to applicable laws and regulations.
5. Your Sample Material may be examined at the time of the Test or thereafter, possibly using new methods or technologies, for the purposes of running the ordered Test or for quality testing.
6. Lucence may de-identify your genetic information and results and use or disclose such de-identified genetic information/ results for future research. You agree that Lucence may retain this de-identified information for future research purposes. You understand that this information will be de-identified in a manner that meets de-identification standards under the United States *Health Information Portability and Accountability Act of 1996*, the Singapore *Personal Data Protection Act 2012*, the Hong Kong *Personal Data (Privacy) Ordinance (Cap 486)* and local data protection laws, as applicable.
7. You understand and agree that Lucence will not re-identify you and notify you in the case of any incidental findings, i.e., non-intended findings that arise and are outside the original purpose for which the Test was conducted.
8. You may, at any time, correct or, have access to your Personal Data, and/or withdraw your consent to any of the above uses of your Personal Data by Lucence (except to the extent that Lucence has already taken action in reliance on your consent). We may charge a reasonable fee for the processing of a request for access to Personal Data.

If you wish to access or correct your Personal Data, please contact us at privacy@lucence.com or visit www.lucence.com/privacy for more details on Lucence's data use practices.

9. On the understanding that you may withdraw consent at any time by checking the box below, or contacting support.asean@lucence.com:
- a. you agree that your genetic information and individually-identifiable data may be used for future research purposes. However, once your genetic information and results have been de-identified such that Lucence is not able to identify you or determine or re-identify which genetic information and results relate to you, you understand that you will no longer be able to withdraw consent to Lucence's future use or disclosure of such de-identified data.
- Risks and benefits of future research
Once the de-identified data has been shared with other parties, you will not have full control over how such de-identified data may be used. Future research may not directly benefit you, but there could be a benefit to society as it advances new detection methods and treatments for cancer.
- b. you hereby assign leftover Sample Material, if any, that is not used for the Test to Lucence for Lucence's and its affiliates' use, including for research. Lucence will endeavor to utilize an appropriate amount of Sample Material for the Test. Lucence will store your leftover Sample Material, in accordance with applicable laws and regulations.
- c. you renounce any rights to your Sample Material and assign to Lucence any intellectual property rights that may be derived from the use of your Sample Material, whether so derived now or in the future.

☐ I want to opt out of this Section 9.

Note: This checkbox is OPTIONAL and Lucence will still be able to run the Test(s) even if you leave this box unchecked.

PATIENT'S RESPONSE

I understand that my physician ordered the Test(s), which includes genetic testing on my behalf.

I hereby declare and confirm that I have been given adequate explanation with respect to the contents of this form, which has been fully explained to me in _____(language), and have fully understood the contents of this form.

I understand that the turnaround time given for the Test(s) is an indicative guide only. As the performance of the Test(s) may require the input of third parties and involve factors that are not within Lucence's control, I understand that Lucence is unable to guarantee the turnaround time. However, Lucence shall keep my physician informed in the event of unusual delays in providing the Test(s) results and my physician shall have the duty to communicate such information to me.

I agree that I shall not hold Lucence liable for any loss of profits, indirect, consequential or special damages which I may suffer or incur in connection with this Test, including but not limited to any delays in the delivery of the Test(s) results or any information provided to me by my physician in reliance on the results of the Test(s). Liability for personal injury or death are not excluded.

By signing this form, I consent to the above terms, except where I have specifically indicated that I do not consent to a term.

Patient's Name _____ Patient's Signature _____ Date _____

Witness is required if language above is not English:

Witness's Name _____ Witness's Signature _____ Date _____

If the patient is unable to give consent:

Parent/ Guardian's Name _____ Parent/ Guardian's Signature _____ Date _____

PHYSICIAN'S STATEMENT

I have explained the above information to this individual. I have addressed the limitations outlined above, and I have answered this person's questions.

Physician's Name _____ Physician's Signature _____ Date _____

Customer support: +65 6592 5102 | sales.asean@lucence.com lucence.com

Lucence Service Laboratory 211 Henderson Road #04-01/02, Henderson Industrial Park, Singapore 159552
Lucence Diagnostics Pte Ltd is licensed by the Ministry of Health (Singapore) as a Clinical Laboratory (Licence Number: L/1710039/CLB/003/222) under the Healthcare Services Act 2020. GST Registered 201605840N. Refer to www.lucence.com/order-terms for Terms of Use. © 2024 Lucence Diagnostics Pte. Ltd. All Rights Reserved.

LucenceINSIGHT™ 5 / LucenceINSIGHT™ Women’s 7*

Genes	ACVR2A	AKT1*	ALK	AMER1	APC	ARID1A	ATM	B2M
	BMPR2	BRAF	BRCA1*	BRCA2*	CBFB*	CDH1*	CDKN1B	CDKN2A
	CTNNB1	EGFR	ERBB2(HER2)	ERBB3	ESR1*	FBXW7	FOXA1*	GATA3*
	GNAS	KEAP1	KRAS	MEN1	MET	MSH6	NF1	NFE2L2
	NRAS	PCBP1	PIK3CA	PPP2R1A*	PTEN	RET	RIT1	RNF43
	RPL22	SMAD4	STK11	TCF7L2	TERT Promoter	TGFBR2	TP53	

*Genes tested only in LucenceINSIGHT™ Women’s 7

LucenceINSIGHT™ 12

Genes	ACVR2A	ADGRG6	AKT1	ALK	AMER1	APC	AR	ARID1A
	ATM	B2M	BCOR	BMPR2	BRAF	BRCA1	BRCA2	CASP8
	CBFB	CCND1	CCR4	CDC27	CDH1	CDKN1A	CDKN1B	CDKN2A
	CREBBP	CTCF	CTNNB1	DICER1	EGFR	EP300	ERBB2(HER2)	ERBB3
	ERCC2	ESR1	FBXW7	FGFR2	FGFR3	FOXA1	GATA3	GNAS
	HRAS	JAK1	KEAP1	KIT	KRAS	MAP2K1(MEK1)	MAPK1(ERK2)	MED12
	MEN1	MET	MSH6	MTOR	NF1	NFE2L2	NOTCH1	NRAS
	PCBP1	PDGFRA	PIK3CA	PIK3R1	POLE	PPP2R1A	PTEN	RET
	RHOA	RIT1	RNF43	RPL22	SMAD4	SPOP	STK11	TCF7L2
	TERT Promoter	TGFBR2	TP53	U2AF1				

LucenceINSIGHT™ 50

Genes	ABL1	ACVR2A	ADGRG6	AKT1	ALK	AMER1	APC	AR
	ARID1A	ASXL1	ATM	B2M	BCOR	BMPR2	BRAF	BRCA1
	BRCA2	BTG1	BTG2	CALR	CASP8	CBFB	CCND1	CCR4
	CD79B	CDC27	CDH1	CDKN1A	CDKN1B	CDKN2A	CIC	CREBBP
	CTCF	CTNNB1	CXCR4	DICER1	DNMT3A	DROSHA	EGFR	EP300
	ERBB2(HER2)	ERBB3	ERCC2	ESR1	EZH2	FBXW7	FGFR1	FGFR2
	FGFR3	FGFR4	FLT3	FOXA1	FOXL2	FOXO1	GATA2	GATA3
	GNA11	GNAQ	GNAS	HRAS	ID3	IDH1	IDH2	IKZF3
	JAK1	JAK2	JAK3	KEAP1	KIT	KRAS	MAP2K1(MEK1)	MAPK1(ERK2)
	MED12	MEN1	MET	MPL	MRPS31	MSH6	MTOR	MYC
	MYCN	MYD88	MYOD1	NF1	NFE2L2	NOTCH1	NOTCH2	NPM1
	NRAS	PCBP1	PDGFRA	PIK3CA	PIK3R1	PLCG1	POLE	PPM1D
	PPP2R1A	PTEN	PTPN11	RAC1	RET	RHOA	RIT1	RNF43
	RPL22	RPS27	RUNX1	SETBP1	SF3B1	SGK1	SMAD4	SMARCB1
	SMO	SOCS1	SPOP	SRSF2	STAG2	STAT3	STAT5B	STK11
	TCF7L2	TERT Promoter	TGFBR2	TP53	U2AF1	VHL	WT1	

Viruses

Epstein-Barr Virus (EBV)	Covered in LucenceINSIGHT™ 50 & LucenceINSIGHT™ Men/Women’s 12
Human Papillomavirus (HPV) 20 Genotypes including 16 and 18	Covered in LucenceINSIGHT™ 50 & LucenceINSIGHT™ Women’s 12

Customer support: +65 6592 5102 | sales.asean@lucence.com

lucence.com

IMPORTANT NOTE:

- 1. Use only the tubes provided inside Lucence Blood Collection kit.
- 2. Improper handling of samples will result in inaccurate analysis of cell-free DNA/RNA.
- 3. Clinics/wards should obtain test kits from their respective outpatient laboratory.

1. COMPLETE FORMS

Ensure both **patient** and **physician** have signed



2. CHECK & LABEL TUBE(S)

Within expiry and labeled with **2 patient identifiers**



3. COLLECTION OF WHOLE BLOOD

Invert 8-10 times after collection

Ensure **minimum volume** and **sample stability** met



4. PREPARE SAMPLE COLLECTION KIT

Place completed **forms** and **copies of other clinical documentation** in box

Parkway Laboratory Services Ltd

2 Aljunied Avenue 1, #04-11

Framework 2 Building

Singapore 389977

For CSF/Effusion fluid samples, please contact Lucence

PHLEBOTOMY SERVICE & SAMPLE COLLECTION

! KEEP SAMPLE AT ROOM TEMPERATURE !
Do **NOT** freeze or refrigerate

NO collection on Sundays and Public Holidays

A. For specialist clinics at Parkway Hospitals:

Mon-Sat: i) Plexus

ii) PLS call centre, 6278 9188

Please follow respective hospital outpatient lab's cut-off timing.

B. For wards at Parkway Hospitals:








Mon-Sat: Obtain kits from respective hospitals' outpatient lab during office hours. Specimen & collection kit should be delivered back to the outpatient lab after the necessary forms and signatories have been collected.

C. For specialist clinics outside Parkway Hospitals:

Call PLS call centre, 6278 9188 during office hours. Cut off timings are:

i) Mon-Fri: 1630 (provide 45 mins notice if clinic closes early)

ii) Sat: 1200 (provide 45 mins notice if clinic closes early)

TEST	SAMPLE REQUIREMENTS	STABLE WITHIN
LiquidHALLMARK®/ LiquidMARK™	 3 Streck Tubes of Peripheral Whole Blood (9mL each, total 27mL)	7 days *96 hrs for ctRNA
LiquidSCREEN™ Lung		
HemeMARK™	 2 Streck Tubes of Peripheral Whole Blood (9mL each, total 18mL) AND / OR  1 EDTA Tube of Bone Marrow Aspirate (Total 3mL)	7 days 5 days
LucenceINSIGHT™ / LucenceINSIGHT™ PLUS	 2 Streck Tubes of Peripheral Whole Blood (9mL each, total 18mL)	7 days
LumiRISK™ / LumiTHERA™ / LumiFOCUS™	 2 Streck/EDTA Tubes of Peripheral Whole Blood (9mL each, total 18mL)	6 days - EDTA 7 days - Streck
NPC GOLD™	 OR  1 Streck/EDTA Tube of Peripheral Whole Blood (Total 9mL)	6 days - EDTA 7 days - Streck

Customer support: +65 6592 5102 | sales.asean@lucence.com

lucence.com